- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07942727
The Effect of Smoking on Salivary and Serum Lipidomic Profiles in Patients With Periodontitis
This observational study aims to investigate how smoking and periodontal health affect lipid profiles in saliva and blood serum. Periodontitis is a chronic inflammatory disease that affects the tissues supporting the teeth, while smoking is an important risk factor for periodontal disease.
The study will include 56 adults divided into four groups according to their periodontal health and smoking status: non-smokers with periodontitis, smokers with periodontitis, periodontally healthy non-smokers, and periodontally healthy smokers.
Saliva and blood samples will be collected from each participant. Lipid profiles will be analyzed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS). The study will examine the individual and combined associations of periodontitis and smoking with lipid profiles and explore the relationship between lipid patterns in saliva and serum.
The findings may help identify lipid-related changes associated with periodontal disease and smoking and improve our understanding of their effects on oral and systemic health.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
Periodontitis is a chronic inflammatory disease characterized by the destruction of tooth-supporting tissues. Smoking is a major modifiable risk factor that influences periodontal inflammation, host immune responses, and disease progression. Both periodontitis and smoking may alter lipid metabolism and contribute to oxidative stress and inflammatory processes.
Lipidomics provides a comprehensive approach to investigating lipid species and metabolic alterations associated with disease. Saliva is a non-invasive biological fluid that may reflect both local oral conditions and systemic biological processes. Comparing salivary and serum lipidomic profiles may provide further insight into the metabolic changes associated with periodontal disease and smoking.
This observational, cross-sectional study will enroll 56 adults aged 18-65 years. Participants will be categorized into four groups based on periodontal status and smoking habits: periodontitis with smoking, periodontitis without smoking, periodontal health with smoking, and periodontal health without smoking.
Periodontal status will be determined through clinical periodontal examination. Saliva and blood samples will be obtained from the same participants, and untargeted lipidomic profiling will be performed using liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (LC-qTOF-MS).
The study will assess the associations of periodontal status and smoking with salivary and serum lipidomic profiles, including their potential interaction. Relationships between lipidomic patterns in the two biological fluids will also be investigated.
This study is expected to contribute to a better understanding of lipid-related biological alterations associated with periodontitis and smoking and may support future research into potential biomarkers of periodontal disease.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Nihan Akdoğan, DDS, PhD
- Puhelinnumero: +905304070848
- Sähköposti: nihanakdogan@yahoo.com.tr
Tutki yhteystietojen varmuuskopiointi
- Nimi: Oğuzhan Durmaz, PhD
- Puhelinnumero: +905369551469
- Sähköposti: durmazogz@gmail.com
Opiskelupaikat
-
-
Ankara
-
Ankara, Ankara, Turkki (Türkiye), 06560
- Rekrytointi
- Ankara University Faculty of Dentistry
-
Ottaa yhteyttä:
- Nihan Akdoğan, DDS, PhD
- Puhelinnumero: +905304070848
- Sähköposti: nihanakdogan@yahoo.com.tr
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
The study population will consist of 56 adults aged 18-65 years, categorized into four groups according to periodontal status and cigarette smoking: (1) patients with periodontitis who smoke, (2) patients with periodontitis who do not smoke, (3) periodontally healthy individuals who smoke, and (4) periodontally healthy individuals who do not smoke. Participants will be evaluated through clinical periodontal examinations, and saliva and serum samples will be collected for lipidomic profiling. All participants must meet the predefined eligibility criteria.
Kuvaus
Inclusion Criteria:
Individuals aged 18 years or older. Individuals who do not use orthodontic appliances Women who are not pregnant or breastfeeding. Individuals without systemic diseases that may affect periodontal health. Individuals who have not used anti-inflammatory and/or antimicrobial medications within the past 6 months.
Individuals who have not received periodontal treatment within the past year.
Exclusion Criteria:
Individuals younger than 18 years. Individuals older than 65 years. Pregnant or breastfeeding women. Individuals who have used anti-inflammatory and/or antimicrobial medications within the past 6 months.
Individuals who have received periodontal treatment within the past year. Individuals with psychiatric disorders. Individuals with any oral infection. Individuals with alcohol dependence. Individuals with active infectious diseases (acute hepatitis, AIDS, or tuberculosis), cancer, or any systemic disease that may affect periodontal tissues.
Individuals receiving medications known to affect periodontal tissues, including phenytoin, cyclosporine A, or calcium channel blockers.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: CROSS_SECTIONAL
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Periodontitis Smokers
Adult participants diagnosed with periodontitis who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontitis Non-Smokers
Adult participants diagnosed with periodontitis who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontally Healthy Smokers
Adult participants with clinically healthy periodontal tissues who are current cigarette smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
|
Periodontally Healthy Non-Smokers
Adult participants with clinically healthy periodontal tissues who are non-smokers. Saliva and serum samples will be collected for lipidomic profiling. |
Saliva samples will be collected from all participants and analyzed using mass spectrometry-based lipidomic techniques to characterize salivary lipid profiles and investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Blood samples will be collected from all participants, and serum will be separated for lipidomic analysis using mass spectrometry-based techniques. Serum lipid profiles will be evaluated to investigate differences associated with periodontal status and cigarette smoking. No therapeutic intervention will be administered. Probing pocket depth (PPD) will be measured in millimeters using a periodontal probe at six sites per tooth. Measurements will be recorded to assess periodontal pocket depth and periodontal disease severity. Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Measurements will be recorded to assess the extent of periodontal attachment loss and periodontal disease severity. Bleeding on probing (BOP) will be assessed at six sites per tooth during periodontal probing. The percentage of sites exhibiting bleeding will be calculated to evaluate gingival inflammation. Plaque index (PI) will be assessed during the clinical periodontal examination to evaluate dental plaque accumulation. Plaque scores will be recorded according to the study protocol. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Salivary Lipidomic Profile
Aikaikkuna: At baseline (single sample collection)
|
Salivary lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status. |
At baseline (single sample collection)
|
|
Serum Lipidomic Profile
Aikaikkuna: At baseline (single sample collection)
|
Serum lipid species and their relative abundances will be measured using mass spectrometry-based lipidomic analysis. Lipidomic profiles will be compared across four groups according to periodontal status and cigarette smoking status. |
At baseline (single sample collection)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Probing Pocket Depth (PPD)
Aikaikkuna: At baseline (single clinical examination)
|
Probing pocket depth (PPD) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean PPD values will be calculated to characterize periodontal status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Attachment Loss (AL)
Aikaikkuna: At baseline (single clinical examination)
|
Attachment loss (AL) will be measured in millimeters at six sites per tooth using a periodontal probe. Mean AL values will be calculated to characterize periodontal tissue destruction, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Bleeding on Probing (BOP)
Aikaikkuna: At baseline (single clinical examination)
|
Bleeding on probing (BOP) will be assessed at six sites per tooth. The percentage of sites exhibiting bleeding will be calculated to characterize gingival inflammation, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
|
Plaque Index (PI)
Aikaikkuna: At baseline (single clinical examination)
|
Plaque index (PI) will be assessed to quantify dental plaque accumulation. Individual plaque index scores will be calculated according to the study protocol to characterize oral hygiene status, evaluate differences between study groups, and investigate correlations with salivary and serum lipidomic profiles. |
At baseline (single clinical examination)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Parodontaaliset sairaudet
- Suun sairaudet
- Stomatognaattiset sairaudet
- Käyttäytyminen
- Tupakan tupakointi
- Tupakan käyttö
- Parodontiitti
- Tupakointi
- Tupakanpoltto
- Terveydenhuollon laatu, saatavuus ja arviointi
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Tutkintatekniikat
- Epidemiologiset menetelmät
- Terapeuttiset lääkkeet
- Biologiset tekijät
- Tiedonkeruu
- Terveydenhuollon arviointimekanismit
- Terveydenhuollon laatu
- Kansanterveys
- Ympäristö ja kansanterveys
- Käyttäytymisen hallinta
- Immobilisaatio
- Bakteeriproteiinit
- Terveystutkimukset
- Tutkimukset ja kyselylomakkeet
- Hammaslääketiede
- Antigeenit
- Hammasterveystutkimukset
- Kansanterveyshammaslääketiede
- Bakteeri
- Painot ja mitat
- Fyysinen
- Tuberkuliini
- Hammaslaatta -indeksi
- short-wavelength opsin
Muut tutkimustunnusnumerot
- 27/2
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Individual participant data (IPD) will not be shared with other researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form through scientific publications without disclosing identifiable participant information.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .